Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.890 +0.090 (+4.99%)
Streaming Delayed Price Updated: 1:58 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Proposed Public Offering of Common Stock
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
From Invivyd
Via GlobeNewswire
News headline image
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
News headline image
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Proposed Public Offering of Common Stock
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.